Interpretation  ||| S:0 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
mild  ||| S:18 E:23 ||| JJ
elevation  ||| S:23 E:33 ||| NN
of  ||| S:33 E:36 ||| IN
high-sensitivity  ||| S:36 E:53 ||| JJ
cardiac  ||| S:53 E:61 ||| JJ
troponins  ||| S:61 E:71 ||| JJ
Measurements  ||| S:71 E:84 ||| NNS
of  ||| S:84 E:87 ||| IN
cardiac  ||| S:87 E:95 ||| JJ
troponins  ||| S:95 E:105 ||| NNS
( ||| S:105 E:106 ||| -LRB-
cTn ||| S:106 E:109 ||| NNP
)  ||| S:109 E:111 ||| -RRB-
are  ||| S:111 E:115 ||| VBP
yet  ||| S:115 E:119 ||| RB
considered  ||| S:119 E:130 ||| VBN
the  ||| S:130 E:134 ||| DT
gold  ||| S:134 E:139 ||| JJ
standard  ||| S:139 E:148 ||| JJ
method  ||| S:148 E:155 ||| NN
in  ||| S:155 E:158 ||| IN
patients  ||| S:158 E:167 ||| NNS
with  ||| S:167 E:172 ||| IN
chest  ||| S:172 E:178 ||| JJ
pain ||| S:178 E:182 ||| NN
.  ||| S:182 E:184 ||| .
Very  ||| S:184 E:189 ||| RB
recently ||| S:189 E:197 ||| RB
,  ||| S:197 E:199 ||| ,
high-sensitivity  ||| S:199 E:216 ||| NNP
( ||| S:216 E:217 ||| -LRB-
hs ||| S:217 E:219 ||| LS
) ||| S:219 E:220 ||| -RRB-
cTn  ||| S:220 E:224 ||| JJ
emerged  ||| S:224 E:232 ||| NN
and  ||| S:232 E:236 ||| CC
allow  ||| S:236 E:242 ||| VB
to  ||| S:242 E:245 ||| TO
measure  ||| S:245 E:253 ||| VB
very  ||| S:253 E:258 ||| RB
low  ||| S:258 E:262 ||| JJ
concentrations  ||| S:262 E:277 ||| NNS
of  ||| S:277 E:280 ||| IN
cTn ||| S:280 E:283 ||| JJ
.  ||| S:283 E:285 ||| .
The  ||| S:285 E:289 ||| DT
aim  ||| S:289 E:293 ||| NN
of  ||| S:293 E:296 ||| IN
these  ||| S:296 E:302 ||| DT
assays  ||| S:302 E:309 ||| NN
was  ||| S:309 E:313 ||| VBD
the  ||| S:313 E:317 ||| DT
better  ||| S:317 E:324 ||| JJR
detection  ||| S:324 E:334 ||| NN
of  ||| S:334 E:337 ||| IN
patients  ||| S:337 E:346 ||| NNS
with  ||| S:346 E:351 ||| IN
acute  ||| S:351 E:357 ||| FW
myocardial  ||| S:357 E:368 ||| FW
infarction  ||| S:368 E:379 ||| FW
( ||| S:379 E:380 ||| -LRB-
AMI ||| S:380 E:383 ||| NNP
) ||| S:383 E:384 ||| -RRB-
.  ||| S:384 E:386 ||| .
The  ||| S:386 E:390 ||| DT
threshold  ||| S:390 E:400 ||| NN
value  ||| S:400 E:406 ||| NN
should  ||| S:406 E:413 ||| MD
be  ||| S:413 E:416 ||| VB
the  ||| S:416 E:420 ||| DT
99th  ||| S:420 E:425 ||| JJ
percentile  ||| S:425 E:436 ||| NN
of  ||| S:436 E:439 ||| IN
the  ||| S:439 E:443 ||| DT
method ||| S:443 E:449 ||| NN
,  ||| S:449 E:451 ||| ,
which  ||| S:451 E:457 ||| WDT
corresponds  ||| S:457 E:469 ||| VBZ
to  ||| S:469 E:472 ||| TO
the  ||| S:472 E:476 ||| DT
concentration  ||| S:476 E:490 ||| NN
obtained  ||| S:490 E:499 ||| VBN
from  ||| S:499 E:504 ||| IN
99 ||| S:504 E:506 ||| CD
%  ||| S:506 E:508 ||| NN
of  ||| S:508 E:511 ||| IN
a  ||| S:511 E:513 ||| DT
reference  ||| S:513 E:523 ||| NN
population ||| S:523 E:533 ||| NN
.  ||| S:533 E:535 ||| .
These  ||| S:535 E:541 ||| DT
assays  ||| S:541 E:548 ||| NN
improve  ||| S:548 E:556 ||| VB
the  ||| S:556 E:560 ||| DT
detection  ||| S:560 E:570 ||| NN
of  ||| S:570 E:573 ||| IN
patients  ||| S:573 E:582 ||| NNS
with  ||| S:582 E:587 ||| IN
elevated  ||| S:587 E:596 ||| JJ
cTn  ||| S:596 E:600 ||| JJ
concentrations ||| S:600 E:614 ||| NNS
.  ||| S:614 E:616 ||| .
All  ||| S:616 E:620 ||| DT
patients  ||| S:620 E:629 ||| NNS
with  ||| S:629 E:634 ||| IN
increased  ||| S:634 E:644 ||| JJ
hs-cTn  ||| S:644 E:651 ||| JJ
concentration  ||| S:651 E:665 ||| NN
above  ||| S:665 E:671 ||| IN
the  ||| S:671 E:675 ||| DT
99th  ||| S:675 E:680 ||| CD
percentile  ||| S:680 E:691 ||| NNS
should  ||| S:691 E:698 ||| MD
be  ||| S:698 E:701 ||| VB
considered  ||| S:701 E:712 ||| VBN
at  ||| S:712 E:715 ||| IN
high  ||| S:715 E:720 ||| JJ
risk  ||| S:720 E:725 ||| NN
of  ||| S:725 E:728 ||| IN
future  ||| S:728 E:735 ||| JJ
clinical  ||| S:735 E:744 ||| JJ
event  ||| S:744 E:750 ||| NN
when  ||| S:750 E:755 ||| WRB
compared  ||| S:755 E:764 ||| VBN
to  ||| S:764 E:767 ||| TO
patients  ||| S:767 E:776 ||| NNS
with  ||| S:776 E:781 ||| IN
lower  ||| S:781 E:787 ||| JJR
concentration ||| S:787 E:800 ||| NN
.  ||| S:800 E:802 ||| .
However ||| S:802 E:809 ||| RB
,  ||| S:809 E:811 ||| ,
these  ||| S:811 E:817 ||| DT
elevated  ||| S:817 E:826 ||| JJ
concentrations  ||| S:826 E:841 ||| NNS
are  ||| S:841 E:845 ||| VBP
not  ||| S:845 E:849 ||| RB
necessarily  ||| S:849 E:861 ||| RB
related  ||| S:861 E:869 ||| VBN
to  ||| S:869 E:872 ||| TO
AMI  ||| S:872 E:876 ||| NNP
due  ||| S:876 E:880 ||| JJ
to  ||| S:880 E:883 ||| TO
coronary  ||| S:883 E:892 ||| VB
artery  ||| S:892 E:899 ||| JJ
plaque  ||| S:899 E:906 ||| JJ
rupture  ||| S:906 E:914 ||| NN
and  ||| S:914 E:918 ||| CC
superimposed  ||| S:918 E:931 ||| JJ
thrombus ||| S:931 E:939 ||| NN
.  ||| S:939 E:941 ||| .
In  ||| S:941 E:944 ||| IN
order  ||| S:944 E:950 ||| NN
to  ||| S:950 E:953 ||| TO
understand  ||| S:953 E:964 ||| VB
adequately  ||| S:964 E:975 ||| RB
cTn  ||| S:975 E:979 ||| JJ
measurement ||| S:979 E:990 ||| NN
,  ||| S:990 E:992 ||| ,
the  ||| S:992 E:996 ||| DT
physician  ||| S:996 E:1006 ||| NN
should  ||| S:1006 E:1013 ||| MD
base  ||| S:1013 E:1018 ||| VB
his  ||| S:1018 E:1022 ||| PRP$
interpretation  ||| S:1022 E:1037 ||| NN
on  ||| S:1037 E:1040 ||| IN
the  ||| S:1040 E:1044 ||| DT
context ||| S:1044 E:1051 ||| NN
,  ||| S:1051 E:1053 ||| ,
the  ||| S:1053 E:1057 ||| DT
cTn  ||| S:1057 E:1061 ||| JJ
concentration ||| S:1061 E:1074 ||| NN
,  ||| S:1074 E:1076 ||| ,
variations  ||| S:1076 E:1087 ||| NNS
during  ||| S:1087 E:1094 ||| IN
serial  ||| S:1094 E:1101 ||| JJ
sampling ||| S:1101 E:1109 ||| NN
,  ||| S:1109 E:1111 ||| ,
and  ||| S:1111 E:1115 ||| CC
the  ||| S:1115 E:1119 ||| DT
possible  ||| S:1119 E:1128 ||| JJ
existence  ||| S:1128 E:1138 ||| NN
of  ||| S:1138 E:1141 ||| IN
a  ||| S:1141 E:1143 ||| DT
coexistent  ||| S:1143 E:1154 ||| JJ
disease  ||| S:1154 E:1162 ||| NN
characterized  ||| S:1162 E:1176 ||| VBN
by  ||| S:1176 E:1179 ||| IN
increased  ||| S:1179 E:1189 ||| JJ
cTn  ||| S:1189 E:1193 ||| JJ
concentrations ||| S:1193 E:1207 ||| NNS
.  ||| S:1207 E:1209 ||| .
